Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:47 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 33,128 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Comparing the Efficacy of Two Ibuprofen Formulations

NCT00740857
View directory record Official record
Conditions
Pain
Interventions
placebo, ibuprofen Formulation 1, ibuprofen Formulation 2
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
16 Years to 40 Years
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Nov 3, 2026, 6:47 AM EST
Completed Phase 2 Interventional Results available

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

NCT02954601
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ORMD-0801 (qd), ORMD-0801 (bid), ORMD-0801 (tid), Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
20 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Nov 3, 2026, 6:47 AM EST
Recruiting Not applicable Interventional

Transspinal Stimulation With and Without Blood Flow Restricted Exercise Via Telehealth in Persons With Tetraplegia

NCT05423600
View directory record Official record
Conditions
Tetraplegia/Tetraparesis
Interventions
BES + TS, Experimental: BES+sham TS
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 6:47 AM EST
Completed Phase 2 Interventional Results available

Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors

NCT01032200
View directory record Official record
Conditions
Brain Tumors, Nervous System Tumors, Cognition Disorders, Fatigue
Interventions
Armodafinil, placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Nov 3, 2026, 6:47 AM EST
Completed Phase 3 Interventional Results available

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

NCT01665144
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
1,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
52
States / cities
Phoenix, Arizona • Berkeley, California • Los Angeles, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Nov 3, 2026, 6:47 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels

NCT07423598
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 3, 2026, 6:47 AM EST
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides

NCT02261493
View directory record Official record
Conditions
Facial Rhytides, Glabellar Rhytides
Interventions
OnabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Nov 3, 2026, 6:47 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults

NCT05428228
View directory record Official record
Conditions
Dehydration, Rehydration, Exercise Performance, Exercise Recovery, Cognitive Performance
Interventions
TP1, TP2, Placebo
Other
Lead sponsor
Liquid I.V.
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Nov 3, 2026, 6:47 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Impact of Duloxetine on Male Fertility

NCT03038867
View directory record Official record
Conditions
Infertility, Male, Depression
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Nov 3, 2026, 6:47 AM EST
Completed Phase 2 Interventional

A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

NCT05309200
View directory record Official record
Conditions
Cirrhosis, Ascites, Hepatorenal Syndrome, Acute Kidney Injury
Interventions
OCE-205, Placebo
Drug
Lead sponsor
Ocelot Bio, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Nov 3, 2026, 6:47 AM EST
Completed Not applicable Interventional Results available

Combining tDCS and CILT in Non-fluent Aphasia

NCT05561400
View directory record Official record
Conditions
Aphasia, Non-fluent Aphasia, Stroke, Brain Injuries
Interventions
tDCS, Placebo
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Nov 3, 2026, 6:47 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Ketone Esters for Optimization of Operator Performance in Hypoxia

NCT07065864
View directory record Official record
Conditions
Hypoxia
Interventions
Ketone ester, Placebo
Dietary Supplement · Other
Lead sponsor
Florida Institute for Human and Machine Cognition
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Pensacola, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Nov 3, 2026, 6:47 AM EST
Terminated Not applicable Interventional

Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women

NCT04556032
View directory record Official record
Conditions
Healthy
Interventions
L-Ergothioneine 10 mg/d, L-Ergothioneine 25 mg/d, Placebo
Dietary Supplement · Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
55 Years to 79 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Nov 3, 2026, 6:47 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Caffeine and Intermittent Hypoxia on Leg Function in Human Spinal Cord Injury

NCT02323698
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Caffeine, AIH, Placebo, SHAM
Drug · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Nov 3, 2026, 6:47 AM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

NCT04118387
View directory record Official record
Conditions
Sleep Disordered Breathing, Able Bodied
Interventions
Acetazolamide + supplemental oxygen + PAP therapy, Zolpidem + PAP therapy, Buspirone + PAP therapy
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 3, 2026, 6:47 AM EST
Terminated Phase 2 Interventional Results available

A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis

NCT00784693
View directory record Official record
Conditions
Endometriosis
Interventions
Tanezumab, Placebo
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
30
States / cities
Mobile, Alabama • Tucson, Arizona • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Nov 3, 2026, 6:47 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021
View directory record Official record
Conditions
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Interventions
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Nov 3, 2026, 6:47 AM EST
Not listed Not applicable Interventional

Study of Vilazodone to Treat Social Anxiety Disorder

NCT01712321
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Vilazodone, Placebo
Drug
Lead sponsor
The Medical Research Network
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Nov 3, 2026, 6:47 AM EST
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)

NCT03279081
View directory record Official record
Conditions
Crohn's Disease
Interventions
Cx601, Placebo
Drug · Other
Lead sponsor
Tigenix S.A.U.
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
68
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 3, 2026, 6:47 AM EST
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

NCT01479465
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Simtuzumab, Placebo to match SIM, Leucovorin, Irinotecan, Fluorouracil
Biological · Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Nov 3, 2026, 6:47 AM EST
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

NCT03569007
View directory record Official record
Conditions
Celiac Disease
Interventions
Larazotide, Matching Placebo
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
160
States / cities
Saraland, Alabama • Scottsdale, Arizona • Tucson, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Nov 3, 2026, 6:47 AM EST
Completed Phase 1 Interventional

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

NCT03479892
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0194-0499, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
22 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Nov 3, 2026, 6:47 AM EST
Completed Phase 3 Interventional Results available

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

NCT02807636
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Atezolizumab, Carboplatin, Gemcitabine, Placebo, Cisplatin
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
18
States / cities
Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Nov 3, 2026, 6:47 AM EST
Completed Not applicable Interventional Results available

DIVINE: Dialysis Infection and Vitamin D In New England

NCT00892099
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Ergocalciferol, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Nov 3, 2026, 6:47 AM EST